Speaker: Jorge Cortes

0:42:47

Santiago Data Visualization: Meetup 2 (2ndSpeaker, Jorge Cortes)

0:26:14

How to Treat Chronic Myeloid Leukemia (CML) - Dr. Jorge Cortes

0:06:20

DIY Mini Boombox Getto Amplificador Blaster sin herramientas Vivitar

0:21:01

13 Is combination therapy ready for prime time in CML? Prof. Jorge Cortes

0:01:46

Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study

0:05:10

Jorge E Cortes ASCO20: Interim Analysis of the Phase II OPTIC Trial of Ponatinib in CP-CML

0:06:36

Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemia

0:06:36

Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemia

0:01:27

The safety and efficacy of Grb2 inhibition with BP1001 in AML

0:01:31

Five-year follow-up of olutasidenib for IDH1-mutated R/R AML

0:01:38

An update on the OPTIC study: adjusting the dose of ponatinib for CP-CML

0:01:01

JORLAN MANDA A REAL SOBRE SER BODYBUILDING #bodybuilding #musculação #jorlanvieira #dorianyates

0:01:35

OPTIC post hoc analyses: OPTIC and PACE comparison & impact of mutations on ponatinib starting dose

0:02:32

Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization

0:01:40

TKI dosage: should clinicians stick to the product monograph recommendations?

0:01:32

Post hoc analysis of OPTIC: patient responses by T315I mutation status

0:18:42

Case Discussion: High-Risk Myelodysplastic Syndromes

0:00:16

Quien ganará?🤔

0:00:15

Cuando el copiloto me ensucia el sillín 👀😅 #humor #eli #motos

0:01:01

Advancements in CML: improving treatment-free remission and novel agents

0:01:22

Responses to olutasidenib in patients with AML who have failed treatment with venetoclax

0:02:21

Exciting updates in the field of CML: disease pathophysiology & novel agents

0:02:12

Key emerging trials in CML and the importance of improving treatment-free remission rates

0:17:58

Elon Musk STUNS Jordan Peterson